{Reference Type}: Case Reports
{Title}: Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib.
{Author}: Nishiyama A;Sato S;Sakaguchi H;Kotani H;Yamashita K;Ohtsubo K;Nanjo S;Yano S;Mizuguchi K;Ikeda H;Takeuchi S;
{Journal}: Front Oncol
{Volume}: 14
{Issue}: 0
{Year}: 2024
{Factor}: 5.738
{DOI}: 10.3389/fonc.2024.1374594
{Abstract}: We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted agents as second-line treatment. Despite a notable initial response, tumor regression lasted only 52 days. A subsequent liquid biopsy revealed additional alterations (BRAF amplification, KIT amplification, TP53 S241F), indicating a complex resistance mechanism. This case underscores the challenges in treating BRAF K601E-mutant lung carcinoma, emphasizing the need for advanced molecular diagnostics, personalized approaches, and further research into more effective therapies for unique genetic profiles.